Pharmaceuticals

PRF Tech

PRF Tech released FY2025 9 Months Earnings on March 26 Post-Market (EST), actual revenue USD 8.5 K, actual EPS USD -6.9005

PRF Tech released FY2025 Q4 earnings on March 26 (EST), actual revenue USD 8.5K, actual EPS USD -1.4473

PRF Tech released FY2025 Q3 earnings on March 26 (EST), actual revenue USD 8.5K, actual EPS USD -1.4473

PRF Tech released FY2025 Annual Earnings on March 26 (EST), actual revenue USD 17K (forecast USD 0), actual EPS USD -7.4663 (forecast USD -241.1999)

PRF Technologies Ltd. Signs SaaS Agreement and Deploys DeepSolar Platform with Shikun & Binui Energy

PainReform Ltd. Completes Development Assessment on LayerBio's Continuous-Release Ophthalmic Drug Delivery Platform

PainReform Announces DeepSolar's AI Report Engine, Rated Poorly by TipRanks

PRF Tech released FY2025 Semi-Annual earnings on October 1, 2025 (EST) with actual revenue of USD 0 and EPS of USD -5.4531

Painreform released FY2025 Q2 earnings on October 1, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.5453

PRF Tech released FY2025 Q1 earnings on October 1, 2025 (EST), actual revenue USD 0, actual EPS USD -2.7265

PainReform Ltd. Collaborates with LayerBio for Ophthalmic Pain Treatment Clinical Trial

Blade Ranger Holds a Large Number of PainReform Warrants

PainReform and Econergy Launch Solar Plant Pilot Project in Romania

PRF Tech released FY2024 Q4 earnings on April 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.7514 (forecast USD -38.4)

PRF Tech released FY2024 Q3 earnings on April 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.7514 (forecast USD -94.8)

Painreform released FY2024 annual earnings on April 7, 2025 (EST), with actual revenue of USD 0 and actual EPS of USD -32.1644 (forecast EPS USD -78.9599)

PRF Tech released FY2024 9 Months Earnings on April 7, 2025 (EST) with actual revenue of USD 0 and EPS of USD -88.557

PainReform's Acquisition Boosts Its Competitiveness in AI Solar Management

PainReform Receives Notification from Nasdaq Regarding Minimum Shareholder Equity Requirements

PainReform Ltd Applies for Mixed Listing

Regentis Biomaterials

Freecast

Cuprina

VS MEDIA

Hyperscale Data

QTREX Quantum

Horizon Quantum

Sadot

RTB Digital

PRFX

HITI

RDHL

CELZ

IMCC

XTLB

During Monday's after-market session, several healthcare stocks experienced significant volatility. Gainers included IM Cannabis (+36.0%), High Tide (+15.99%), and XTL Biopharmaceuticals (+8.69%). Conversely, losers featured PRF Technologies (-25.3%), Redhill Biopharma (-12.05%), and Creative Medical Tech (-11.3%). These movements occurred alongside earnings reports for some companies.

benzinga_article

High Tide

Redhill Biopharma

Creative Medical Tech

IM Cannabis

XTL BioPharma

Lexaria Bioscience

Anixa Biosciences

Cosmos Health

Alvotech SA

Scinai Immunotherapeutics

LEXARIA BIOSCIENCE CORP C/WTS 14/01/2026 (TO PUR COM)

Alvotech SA - CW 27

12 Health Care Stocks Moving In Monday's After-Market Session

GNTA

TTRX

NXTC

During Monday's intraday session, several healthcare stocks experienced significant volatility. Gainers included AIM ImmunoTech (+126.8%), Genenta Science (+74.74%), and Turn Therapeutics (+26.34%). Conversely, notable losers were PRF Technologies (-35.0%), Oculis Holding (-34.87%), and NextCure (-30.63%). The report highlights specific price movements and market capitalizations for these companies.

Genenta Science S.P.A.

AIM ImmunoTech

Turn Therapeutics

Oculis Holding AG

NextCure

Conexeu Sciences

HeartSciences

Outlook Therapeutics

Co-Diagnostics

Akanda

Immuneering

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

HEARTSCIENCES INC C/WTS (TO PUR COM)

OCULIS HOLDING AG C/WTS 06/03/2028 (TO PUR ORD)

12 Health Care Stocks Moving In Monday's Intraday Session

PRF Tech fell 34.00%; Eli Lilly fell 2.39%, with a transaction volume of USD 610 million; Johnson & Johnson fell 1.64%, with a transaction volume of USD 300 million; Pfizer fell 2.43%, with a transaction volume of USD 239 million; Merck fell 2.97%, with a market value of USD 284.5 billion

Price Alert

Eli Lilly

Johnson & Johnson

Pfizer

Merck

U.S. Stock Market Midday Update: PRF Tech Plummets 34%: FDA Good News Fails to Mask Technical Breakdown, Overbought Risks Weigh on Stock Price

Why Is Penny Stock PRF Technologies (PRFX) Up Today?

businessinsider

Why Is Penny Stock PRF Technologies (PRFX) Up Today?

CODX

During Friday's intraday session, several healthcare stocks experienced significant volatility. Gainers included PRF Technologies (+231%), CDT Equity (+120%), and Replimune Group (+80%). Conversely, notable losers were Aditxt (-27%), Aethlon Medical (-24%), and Co-Diagnostics (-24%). The report highlights substantial price swings across various NASDAQ-listed companies in the health care sector.

CDT Equity

Aditxt

Replimune

Aethlon Medical

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares US Medical Devices

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

VanEck Biotech ETF

Ark Genomic Revolution ETF

Proshares UltraShort Nasdaq Biotech

iShares Biotechnology ETF

iShares Global Healthcare

ALPS Medical Breakthrough

SPDR S&P Health Equip

iShares US Pharma

Direxion S&P Biotech Bull 3X

Direxion S&P Biotech Bear 3X

VG Health

Clearmind Medicine

Scilex

C4 Therapeutics

Akari Therap

Agape ATP

SciSparc

CDT EQUITY INC C/WTS 22/09/2028(TO PUR COM)

12 Health Care Stocks Moving In Friday's Intraday Session

PRF Technologies Ltd. (NASDAQ:PRFX) shares surged 186.22% to $3.92 in after-hours trading following an update on its AI-driven energy platform, DeepSolar Predict. This platform aids renewable operators in managing solar, wind, and battery storage assets. The company also received FDA clearance for a new drug application. Despite the surge, PRFX has seen an 85.43% drop over the past year, with a market cap of $1.19 million.

NVIDIA

Kratos Defense & Security

Shutterstock

NVIDIA Corporation

PRF Technologies (PRFX) Shares Surge Over 186% After Hours: Here's What Is Going On

PRF Technologies has received FDA IND clearance for its drop-less cataract surgery pain therapy, OcuRing-K, allowing it to advance to a Phase 2 trial. This bio-erodible intraocular ring aims to simplify post-operative care by delivering medication directly to the surgical site, potentially eliminating the need for eye drops. The trial is set to begin enrolling patients in late 2026, focusing on pain reduction and safety. PRF's shares fell 7.05% to $2.11, nearing a 52-week low.

EXCLUSIVE: PRF Technologies Advances Drop-Less Drug For Cataract Surgery Pain

PRF Technologies (NASDAQ:PRFX) shares fell on Tuesday following a year-end business update outlining its healthcare and AI-driven solar initiatives. The company highlighted a majority investment in LayerBio and the acquisition of DeepSolar, aiming to enhance its ocular drug-delivery and solar analytics sectors. Despite a cash position of $4.1 million, PRFX is trading significantly below its moving averages, indicating a bearish trend. The stock is down 76.25% over the past year, with key resistance at $2.50 and support at $2.00. Earnings are expected on April 21, 2026.

What's Going On With Pharma Company PRF Technologies On Tuesday?

PRF Tech(PRFX.US)

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. Stock Market Midday Update: PRF Tech Plummets 34%: FDA Good News Fails to Mask Technical Breakdown, Overbought Risks Weigh on Stock Price

Why Is Penny Stock PRF Technologies (PRFX) Up Today?

12 Health Care Stocks Moving In Friday's Intraday Session

PRF Technologies (PRFX) Shares Surge Over 186% After Hours: Here's What Is Going On

EXCLUSIVE: PRF Technologies Advances Drop-Less Drug For Cataract Surgery Pain

What's Going On With Pharma Company PRF Technologies On Tuesday?